- Home
- ORLA vs DNLI Comparison
ORLA vs DNLI Comparison
Compare ORLA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORLA
- DNLI
- Stock Information
- Founded
- ORLA 2007
- DNLI 2013
- Country
- ORLA Canada
- DNLI United States
- Employees
- ORLA N/A
- DNLI N/A
- Industry
- ORLA Precious Metals
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ORLA Basic Materials
- DNLI Health Care
- Exchange
- ORLA Nasdaq
- DNLI Nasdaq
- Market Cap
- ORLA 2.3B
- DNLI 2.1B
- IPO Year
- ORLA N/A
- DNLI 2017
- Fundamental
- Price
- ORLA $10.54
- DNLI $13.66
- Analyst Decision
- ORLA Hold
- DNLI Strong Buy
- Analyst Count
- ORLA 1
- DNLI 15
- Target Price
- ORLA $6.00
- DNLI $33.85
- AVG Volume (30 Days)
- ORLA 2.1M
- DNLI 1.6M
- Earning Date
- ORLA 08-11-2025
- DNLI 07-31-2025
- Dividend Yield
- ORLA N/A
- DNLI N/A
- EPS Growth
- ORLA N/A
- DNLI N/A
- EPS
- ORLA 0.01
- DNLI N/A
- Revenue
- ORLA $417,310,000.00
- DNLI N/A
- Revenue This Year
- ORLA $158.56
- DNLI N/A
- Revenue Next Year
- ORLA $13.13
- DNLI $335.74
- P/E Ratio
- ORLA $2,143.86
- DNLI N/A
- Revenue Growth
- ORLA 67.06
- DNLI N/A
- 52 Week Low
- ORLA $3.24
- DNLI $10.57
- 52 Week High
- ORLA $12.43
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ORLA 52.73
- DNLI 42.98
- Support Level
- ORLA $10.48
- DNLI $13.57
- Resistance Level
- ORLA $11.49
- DNLI $14.88
- Average True Range (ATR)
- ORLA 0.52
- DNLI 0.71
- MACD
- ORLA -0.02
- DNLI -0.06
- Stochastic Oscillator
- ORLA 29.23
- DNLI 7.83
About ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Mexico, and the South Railroad and Lewis gold projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.